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Abstract
MicroRNAs (miRNAs) represent a class of small non-coding RNAs that control gene expression
by targeting messenger RNA (mRNA). Recently, it has been demonstrated that miRNA expression
is altered in many human diseases including cancers, suggesting that miRNA may play a potential
role in the pathogenesis of different diseases. It has also been reported that there is a unique
expression pattern of miRNAs in the disease state differing from the normal state. In this review,
we focus on the miRNA signatures in different human diseases including cancers. Such signatures
may be used as diagnostic and prognostic markers.
Discovery of microRNA
Discovered in 1993 from nematode Caenorhabditis elegans,
miRNA are small, non-coding RNAs composed of 18–24
nucleotides. They act by negatively regulating gene expres-
sion at the post-transcriptional level through modulation
of mRNA expression. Lee et al. [1] found that lin-4, an
important gene that is important for post-embryonic
development of C. elegans, does not code for a protein.
Instead, it is transcribed into a 22-nucleotide RNA mole-
cule. Seven years later, a second miRNA, let-7, also
emerged from C. elegans genetic screening. The discovery
of many new miRNAs has continued there after, with evi-
dence emerging to suggest these small RNAs play a crucial
role in gene regulation. This role has been confirmed by
the identification of hundreds of conserved miRNA
sequences in nematodes, flies, and mammals [2].
To date, more than 3% of the genes in humans have been
found to encode for miRNAs. Anywhere from 40% to
90% of the human protein encoding genes are under
miRNA-mediated gene regulation [3]. MiRNAs exert their
effect by negatively regulating gene expression through
one of two mechanisms, i.e., mRNA degradation or trans-
lational suppression. The mechanism by which the
miRNA proceeds is dependent on the complementarity
between the miRNA and its mRNA target [4]. A high level
of complementarity corresponds to the degradation of the
target mRNA via the RNA-mediated interference (RNAi)
pathway. When there is inadequate complementarity,
miRNAs bind to the untranslated region of the target
mRNAs and translational suppression occurs through a
RNA-induced silencing complex (RISC). Plants more
commonly utilize the first mechanism while animals
employ the second [2].
MiRNAs play an important role in different biological
process such as cell proliferation during development, cell
growth, and organization as well as apoptosis, biogenesis,
transcription, signal transduction, cell cycle, neurogene-
sis, and fat metabolism. The deregulation of miRNA func-
tion can lead to human diseases as the target genes of
miRNA are involved in several metabolic disorders such
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as various forms of cancers, lymphomas, diabetes and
neurological disorders such as Parkinson's and Alzhe-
imer's diseases. Recently, there has been considerable
interest in understanding the mechanism of the RNA reg-
ulatory phenomena and how miRNA functions in car-
cinogenesis. Specifically, determining how the regulation
of miRNA may be targeted to develop cancer therapies has
been a focus. In this review, we discuss recent discoveries
related to miRNA in different cancer diagnoses and, in
particular, treatment related to ovarian cancer (OVCA).
Biogenesis of miRNA
Like proteins, miRNAs are transcribed from DNA into a
primary (Pri) RNA transcript. In the first step, formation
of Pri-miRNA inside the nucleus occurs from the tran-
scription of the miRNA gene by RNA polII. The Pri-
miRNA is capped, polyadenylated, and then processed by
RNAase III endonuclease Drosha and the double stranded
(ds) RNA-binding protein Pasha. This processing results
in the formation of a 60 to 70 nucleotide stem loop pre-
cursor (Pre) called Pre-miRNA. The Pre-miRNA is then
transported to the cytoplasm by the Ras-related nuclear
protein-guanosine-5'-triphosphate (RAN-GTP)-depend-
ent export receptor Exportin-5. Next, the Pre-miRNA is
cleaved at the base of the loop by a second RNase III endo-
nuclease, a cytoplasmic Dicer [5]. This forms a transient,
double stranded miRNA (dsmiRNA) of 22 nucleotides in
length. The dsmiRNA complex then enters the miRNA-
associated multiprotein RISC (miRISC), which contains
the Argonuate 2 protein, and the mature miRNA is
retained in the miRISC complex [2]. Argonuate proteins
are active RNase enzymes and extremely conserved in the
RISC. The mature miRNA is now capable of regulating its
target mRNAs (See Fig. 1). Deregulation of this processing
results in perturbation in miRNA genesis and may have
oncogenic consequences.
Role of miRNAs in disease
Gene regulation by miRNA can affect a wide variety of cell
functions, such as regulation of cell differentiation, prolif-
eration, and apoptosis. MiRNAs are important for normal
cell functioning; dysfunction of the miRNA regulation sys-
tem results in disruption of the normal cellular activity
leading to induction of a disease.
MiRNAs in neurodegenerative diseases
Neurodegenerative diseases are the result of the deteriora-
tion of neurons, which leads to disabilities and the possi-
bility of death. Studies have shown that gene defects play
an important role in the pathogenesis of neurodegenera-
tive diseases such as Parkinson's, Alzheimer's, and Hunt-
ington's [6].
Parkinson's disease is the second most prevalent age-asso-
ciated neurodegenerative disorder. Like Alzheimer's dis-
ease, gene mutations can result in inherited forms of
Parkinson's disease [7]. Kim et al. [8] suggest that miRNAs
are essential for maintaining the dopaminergic neurons in
the brain. Given that Parkinson's disease is characterized
by an extreme loss of dopaminergic neurons, it could be
possible that miRNAs play a role in the disease pathogen-
esis. These investigators [8] hypothesized that inducing
alterations in the miRNA networks of the brain results in
neurodegenerative disorders to some extent. Based on the
results of this study and from information obtained in
previous work performed with mice [9], flies [10] and cul-
tured neurons [8] in which the enzyme Dicer was geneti-
cally inactivated, Kim et al. [8] concluded that loss of
Dicer results in complete inactivation of miRNA and is tre-
mendously detrimental [11]. Moreover, Dicer was shown
to be important for neuronal survival, as the loss of miR-
NAs may result in development and/or progression of
Parkinson's disease [8,9].
Spinal muscular atrophy (SMA) is a common genetic dis-
ease characterized by the progressive degeneration of
motor neurons. It has been demonstrated that deletion or
loss-of-function mutations in the survival of motor neu-
ron (SMN) protein results in SMA [12]. Gemin 3 and
Gemin 4 are shared components of SMN and miRNA-
containing ribonucleoprotein particles (miRNPs). Dele-
tion or loss-of-function mutations of SMN in SMA may
affect the activity of miRNPs due to possible redistribu-
tion or changes in the levels of Gemin 3 and 4.
Using RNA immunoprecipitation 3'-end labeling and
miRNA cloning, Dostie and colleagues [13] identified 53
novel miRNAs from mouse and human cell lines, out of
which several were found to be phylogenetically con-
Systematic miRNA biosysnthesis and trafficking to cytoplasm Figure 1
Systematic miRNA biosysnthesis and trafficking to 
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served. Additionally, several miRNAs that were discovered
to be components of miRNPs in these cells seem to repre-
sent distinct subfamilies, all of which contain multiple
copies of these miRNAs on different chromosomes. As
such, it can be proposed that these miRNAs function to
regulate gene expression.
Julie Bilen and colleagues [14] isolated miRNA bantam
(ban) in the genetic screen for the modulators of patho-
genecity of the human neurodegenerative disease model
in Drosophila. They demonstrated that upregulation of
ban mitigated degeneration induced by the pathogenic
polyglutamine (polyQ) protein Ataxin 3, which was
mutated in human polyQ disease spinocerebellar ataxia
type 3 (SCA 3). They also showed that loss of all miRNAs
by Dicer mutation dramatically enhances pathogenic
polyQ protein toxicity in flies and human HeLa cells.
These studies suggest that miRNAs may be important for
neuronal survival in relation to neurodegenerative dis-
ease.
MiRNAs in heart diseases
The heart responds to chronic and acute injury by hyper-
trophic growth. Cardiomyocyte hypertrophy is the domi-
nant cellular response to virtually all forms of
hemodynamic overload, endocrine disorders, myocardial
injury, or inherited mutations in the various structural
and contractile proteins [15]. Multiple genes are aber-
rantly expressed in hypertrophic cardiac cells. Using
microarray analysis, miRNA expression pattern in hearts
revealed that miR-1, miR-29, miR-30, miR-133, and miR-
150 have often been found to be down-regulated while
miR-21, miR-125, miR-195, miR-199, and miR-214 are
up-regulated with hypertrophy.
MiR-21 is found to be consistently induced by cardiac
stress and appears to function as a regulator of cardiac
growth and fetal gene activation in primary cardiomyo-
cytes in vitro. Its role in myocyte hypertrophy was demon-
strated by Cheng et al. in 2007 [16]. Their study showed
that knockout of miR-21 by an inhibitor suppresses cardi-
omyocyte hypertrophy induced by angiotensin II in cell
culture experiments [16]. This indicates that overexpres-
sion of miR-21 has a functional role in cardiac hypertro-
phy. Tatsuguchi et al. [17] also confirmed the role of miR-
21 in cardiac hypertrophy using locked nucleic acid mod-
ified oligos. Recently, Sayed et al. [18] reported that miR-
21 modulates the cellular outgrowths during hypertrophy
through the regulation of sprouty 2, an intracellular
inhibitor of mitogen-activated protein-kinase signaling.
Another miRNA that is consistently up regulated in rodent
and human hypertrophic hearts is miR-195. Forced
expression of miRNA-195 in transgenic mice is sufficient
to induce hypertrophic growth and also results in dilated
cardiomyopathy and heart failure [19].
MiR-208 is encoded within intron 27 of the α major his-
tocompatibility complex (MHC) gene and plays a key role
in the expression of β MHC in response to cardiac stress
[20]. Although the expression level of miR-208 remains
stable during cardiac stress, this miRNA appears to fulfill
a dominant function in regulating cardiac hypertrophy
and remodeling. In response to pressure overload by tho-
racic aortic constriction, the knock-out mice show virtu-
ally no hypertrophy of cardiomyocytes or fibrosis and are
unable to up regulate the β MHC expression [19]. MiR-
208 is supposed to act by repressing the expression of a
common component of stress-response and thyroid hor-
mone signaling pathways in the heart, that of the thyroid-
hormone-receptor (TR) co-regulator TR-associated pro-
tein 1 (THRAP1).
MiR-1 is a muscle-specific miRNA that forms a bicistronic
cluster with miR-133. Both miRNAs belong to the same
transcriptional unit and have been found to play a crucial
role in determining when cardiomyocyte hypertrophy
occurs [21]. While both miRNAs are expressed at low lev-
els in the mouse and human models of cardiac hypertro-
phy, their overexpression can inhibit cardiac hypertrophy.
MiRNAs in diabetes
Diabetes is a chronic disease caused by defects in insulin
production, secretion, and signaling [22]. Poy et al. [12]
reported that overexpression of miR-375 resulted in sup-
pressed glucose-stimulated insulin secretion and its inhi-
bition resulted in enhanced insulin secretion.
Myotrophin, a protein that has a role in exocytosis, was
identified as one of the targets of miR-375. Inhibition of
Myotrophin production has similar effects of miR-375 on
insulin secretion, making miR-375 an important modula-
tor of β-cell function. Keller et al. [23] suggested the addi-
tional targets of miR-375 could be the pancreatic
transcription factors pdx-1 and NeuroD1. This indicates
that miR-375 may play important role in interacting with
transcription factors that control pancreatic maintenance
and development [24].
MiRNA and carcinogenesis
Recent studies show that several miRNAs are differentially
expressed in several human cancers, which indicate that
miRNAs may have a role in the carcinogenic processes
(See Table 1). In 2002, Calin et al. [25] correlated aberrant
miRNA expression with cancer. The first study that was
reported regarding the abnormalities in miRNA expres-
sion was in miR-15a and miR-16-1 in B-cell chronic lym-
phocytic leukemia (CLL); [25]. The study showed that
miRNA 15 and miRNA 16 genes are located in a deleted
region present in more than half of B-cell CLL cases and
that both of the genes are deleted/mutated in more than
half of the in CLL cases. In addition, miR-17-92, which is
present as a cluster of miRNAs on chromosome 13, was
reported to be associated with B cell lymphoma [26].Journal of Ovarian Research 2009, 2:11 http://www.ovarianresearch.com/content/2/1/11
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Table 1: Differentially expressed miRNAs in various cancers.
miRNAs Cancer types Reference
mir-17-92 cluster β-cell lymphoma lung carcinoma Hayashita et al. (2005) [36]
lung carcinoma Hayashita et al. (2005) [36]
miR-145 colon, breast, lung and Prostate Cummins et al. (2006) [47]
Akao et al. (2006) [48]
Bandres et al. (2006) [49]
Iorio et al. (2005) [27]
Michael et al. (2003) [28]
Yanaihara et al. (2006) [50]
miR-15a and miR-16-1 chronic lymphocytic leukemia (CLL) Calin et al. (2005) [51]
miR-221 papillary thyroid carcinoma He et al. (2005b) [52]
miR-21 glioblastoma Chan et al. (2005) [53]
miR-122a Hepatocellular carcinoma Kutay et al. (2006) [54]
miR-125a, miR-139 Gramantieri et al. (2007) [55]
miR-150, miR-145 Meng et al. (2007) [56]
Jiang et al. (2008) [57]
miR-205 Ovary, Lung, Bladder, Head and Neck Ioria et al. (2007) [4]
Yanaihara et al. (2006) [50]
Gottardo et al. (2007) [58]
Tran et al. (2007) [59]
miR-183 Bladder, Colonrectal Gottardo et al. (2007) [58]
Bandres et al. (2006) [49]
miR-95 Cervix Cheng et al. (2005) [60]
miR-155 Breast, Lung, Pancreas, CLL Iorio et al. (2005) [27]
Yanaihara et al. (2006) [50]
Gironella et al. (2007) [42]
Lee et al. (2007) [61]
Fulci et al. (2007) [62]
miR-200a Ovary Iorio et al. (2007) [4]
miR-301 Pancreas Gironella et al. (2007) [42]
Lee et al. (2007) [61]
miR-141 Ovary Iorio et al. (2007) [4]
miR-106a Endomertium, Boren et al. (2008) [63]
Neuroblastoma, Schulte et al. (2008) [64]
T-cell leukemia Landais et al. (2007) [65]
miR-17-5p Bladder and Lung Gottardo et al. (2007) [58]
Matsubara et al. (2007) [66]
miR-34a Ovary, Lymphocytic Iorio et al. (2007) [4]
leukemia Zanette et al. (2007) [67]
miR-200c Ovary Iorio et al. (2007) [4]
miR-23a Lung Yanaihara et al. (2006) [50]Journal of Ovarian Research 2009, 2:11 http://www.ovarianresearch.com/content/2/1/11
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Other miRNAs that have been discovered to be abnor-
mally expressed in cancerous tissues include: miR-145,
which is down regulated in breast cancer [27] ovarian can-
cer [4]; miR-10b, which is found to be mostly down regu-
lated in breast cancer [27]; and miR-145, which has
reduced expression in colorectal cancer [28].
MiRNAs participate in various biological processes
including cell differentiation, proliferation, apoptosis,
stress resistance, and fat metabolism [29] and often have
dual functions. For instance, in some types of cancers,
they possess oncogenic activity, while in others they can
suppress tumor development. Michael et al. [28] showed
that miR-143 and mi-R-145 have been associated with the
reduction of some malignancies, suggesting their poten-
tial tumor suppressing activities. Additional studies dem-
onstrated that miRNAs were found to suppress BCL2, an
anti-apoptotic gene [30]; supporting the idea that miRNA
can also have oncogenic activity. Furthermore, miR-372
and miR-373 cooperate with oncogenic Ras in the cellular
transformation of testicular germ cell tumors [31]. Addi-
tionally, in the Let-7 family, Let 7a-2 and Let 7a-3 are
down regulated in lung cancer and Ras is frequently
mutated [32]. Let-7b is involved in Ras regulation and
inhibits cell cycle progression in melanoma [33,34].
MiR-17-92 has been shown to function in embryogenesis
[35] and is overexpressed in lung cancer, especially in
small cell lung cancer, which is characterized by neuroen-
docrine differentiation. In addition to being overex-
pressed, there are an increased number of gene copies.
This suggests they have a role in the development of lung
cancer [36]. MiR-34a, which is absent in pancreatic cells,
was directly trans-activated by the p53 gene and proved to
be associated with modulation of gene expression initi-
ated by p53 [37]. C-MYC, a proto-oncogene, encodes for
a transcription factor that is responsible for cell prolifera-
tion and growth. A mutation in this gene results in most
common abnormalities associated with human cancers.
Finally, using microarray-based large scale profiling,
Volinia et al. [38] analyzed the miRNA expression pattern
in 540 normal and tumor samples from six types of tissues
(lung, breast, stomach, prostate, colon, and pancreas).
They proved that the abnormal expression pattern of
many miRNAs is connected to carcinogenesis.
For additional information regarding differential expres-
sion of miRNAs in various cancers including glioblasto-
mas, colorectal neoplasia, hepatocellular carcinoma,
papillary thyroid carcinoma etc. ' [see Additional file 1]'.
MiRNAs in human ovarian carcinoma (OVCA)
OVCA is the most common of the gynecologic malignan-
cies, but little is known about the molecular genetics of its
initiation and progression. Epithelial OVCA (EOC),
which accounts for approximately 90% of OVCAs, contin-
ues to be the leading cause of death resulting from gyne-
cological malignancies [39]. Histologically, OVCA is
divided into different subgroups such as serous, muci-
nous, endometrioid, clear cell, Brenner, and undifferenti-
ated carcinomas [40]. The high mortality rate of this
disease is due to late stage diagnosis for more than 70% of
affected patients (Chemoresistance). Trans-vaginal ultra-
sound and serum CA-125 remain poor tests for diagnos-
ing the disease in its early stage and, as a result, most cases
are still more likely to be detected at the advanced stage
[41].
New, more effective diagnostic tests must be developed to
identify OVCA in its early stage. If OVCA is diagnosed in
the early stage, current treatments will be more successful,
which in turn will significantly reduce the high mortality
rate. The discovery that miRNAs are expressed at different
levels in normal versus malignant tissues offers the possi-
bility of identifying new methods of diagnosing early
stage incidence and discovering new therapies for the
treatment of OVCA.
With the advent of new miRNA technology, it is possible
to plan appropriate treatments and predict chemotherapy
outcomes. Studies have shown that miRNAs, which are
noncoding regulatory RNA products, are aberrantly
expressed in many cancer types including breast [27], pan-
creatic [42], and lung cancer [4]. In addition to these
forms, a study conducted by Iorio et al. in 2007, [4] con-
firmed that miRNAs are also abnormally expressed in
OVCA (See Table 2). It was concluded that in the cancer-
ous tissues, i.e., miR-141, miR-200a, miR-200b, and miR-
200c, had the highest level of up-regulation while miR-
125b, miR-140, miR-145, and miR-199a were the most
down-regulated. Moreover, this study demonstrated that
the levels of expression between the normal and malig-
nant ovaries were so drastic that expression levels alone
could distinctly distinguish between tissue types. This
finding is extremely significant because it points to the
possibility that miRNAs may have oncogenic or tumor
suppressing activities.
In addition to the difference in expression levels between
normal and cancerous tissues, it has been shown that
miRNAs can also be histotype-specific. In endometrioid
tumors, miR-21, miR-182, and miR-205 are considerably
overexpressed while miR-144, miR-222, and miR-302a
have reduced expression compared to normal. However,
in serous and clear cell tumors, these miRNAs are nor-
mally expressed [4]. These findings suggest that while all
types of OVCA are currently treated with the same stand-
ard therapies, a more effective course of treatment could
be targeted towards specific histotypes of various cancers.Journal of Ovarian Research 2009, 2:11 http://www.ovarianresearch.com/content/2/1/11
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The above tests are invasive procedures because they
require a tissue sample to determine the expression levels
of miRNAs for diagnostic purposes. However, a new non-
invasive approach has recently been discovered that only
requires a serum sample from the patient. In the serum of
OVCA patients, miRNAs 21, 29a, 92, 93, and 126 were
overexpressed while miRNAs 127, 155, and 99b were
under expressed as compared to controls. This indicates
that a patient's serum miRNA level could be used to
potentially diagnose OVCA. Additionally, miRNAs 21, 92,
and 93 were also overexpressed in patients with normal
CA125 levels. This suggests that earlier diagnosis of OVCA
may be possible through the identification of these miR-
NAs even though patients may present with normal CA-
125 levels [43].
Another new non-invasive method with the potential for
diagnosing OVCA involves isolating tumor-derived exo-
somes. Exosomes are saucer shaped nanovesicles (30–100
nm) that are normally released by multiple mammalian
cell types and have a significant role in cell-to-cell com-
munication. In addition to exosomes released by normal
proliferating cells, tumor cells also release exosomes.
Tumor cells release exosomes at a much higher level than
normal cells and the exosomes also display numerous
tumor antigens that mirror the primary tumor cells. There-
fore, it is proposed that these tumor-derived exosomes
could be used as a diagnostic biomarker. In addition to
the antigens, circulating tumor-derived exosomes have
been shown to contain miRNAs that parallel those of the
original tumor [44]. This demonstrates that miRNA profil-
ing can be executed and accurately represent the originat-
ing tumor through a blood sample rather than requiring
the more invasive tissue sample. It has been shown that
eight particular miRNAs are of diagnostic significance in
OVCA. MiRNA 21, 141, 200a, 200b, 200c, 203, 205, and
214 are all overexpressed in tumor cells and tumor-
derived exosomes. The levels are different enough to
clearly distinguish between benign and malignant tumors
as well [44].
The current treatment utilized for patients with OVCA
consists of primary cytoreductive surgery followed by plat-
inum and taxane combination chemotherapy treatments.
This method of therapy is initially successful; however,
most of the patients become resistant to the platinum-
based chemotherapy [45]. Recent studies indicate that
there are significant differences in the level of miRNA
expression between chemotherapeutic sensitive and
resistant OVCA cell lines and tissues. Boren et al. [45]
found that 27 miRNAs were connected to OVCA cell line
sensitivity to platinum-based chemotherapeutic agents
and the differential expression of these miRNAs leads to
chemoresistance. In the cells resistant to the drugs, 18
miRNAs were up-regulated and 9 were down-regulated. It
was determined that increased expression of miR-181a,
miR-181b, and miR-213 in OVCA cell lines results in
resistance to doxorubicin and gemcitabine and increased
expression of miR-99b and miR-14 leads to docetaxel and
paclitaxel resistance. Eitan et al. [46] also discovered sev-
eral miRNAs that were differentially expressed in stage 3
ovarian tumors. It was established that increased expres-
sion of miR-23a, miR-27a, miR-30c, let-7g, and miR-
199a-3p corresponds to resistance to platinum-based
chemotherapy while reduced expression of miR-378 and
miR-625 relates to resistance.
The difference in miRNA expression levels between chem-
otherapy-sensitive and resistant cells is clinically signifi-
cant. New treatments could exploit these differences if the
Table 2: Differentially expressed miRNAs in ovarian cancer.
miRNAs Up/Down-regulated Reference
miR-21, miR-92, miR-93, miR-126, miR-29a up-regulated Resnick et al., 2009[43]
miR-155, miR-127, miR-99b down-regulated Resnick et al., 2009[43]
miR-200a, miR-141, miR-200c, miR-200b up-regulated Iorio et al., 2007[4]
Zhang et al., 2006 [39]
miR-199a, miR-140, miR-145, miR-125b1 down-regulated Iorio et al., 2007 [4]
Zhang et al., 2006 [39]
miR-100, miR-199a, miR-295, miR-29a, miR-29c, miR-99a, miR-494 up-regulated Dahiya et al., 2008 [68]
Kerscher et al., 2006 [2]
let-7d, miR-106b, miR-122a, miR-141, miR-183, miR-195, miR-200a, miR-335, miR-424, miR-155, 
miR-488, let-7a
down-regulated Dahiya et al., 2008 [68]
Iorio et al., 2007 [4]
Zhang et al., 2006 [39]Journal of Ovarian Research 2009, 2:11 http://www.ovarianresearch.com/content/2/1/11
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mechanism behind regulating miRNA expression is deter-
mined. Then, for instance, miR-378, which is down-regu-
lated in malignant ovarian tissue, could be induced to
over express to a normal level, possibly making the cells
more sensitive to platinum-based chemotherapy. Moreo-
ver, identification of specific miRNAs between types of
cancers (lung, ovarian, pancreatic) and even within types
(endometrioid, clear cell, serious in ovarian) could allow
for more personalized treatments, which certainly present
the chance for a better prognosis.
While there is not much information currently available
on the mechanisms responsible for inducing aberrant
miRNA expression, there is a new possible explanation for
their overexpression in OVCA. Iorio et al. [4] recently
proved that treating OVCAR3 cells with 5-aza-2' deoxycy-
tidine, a demethylating treatment, results in the overex-
pression of miR-21, miR-203, and miR-205. These
miRNAs are also up-regulated in ovarian malignant
tumors. This indicates that the mechanism causing their
up-regulation in vivo could be DNA hypomethylation.
Conclusion
The discovery of aberrant miRNA expression between
control patients and those with OVCA holds great prom-
ise for improved patient care and more positive outcomes.
Thus, identification of altered miRNA expression, as well
as their targets, provides new opportunities for therapeu-
tic strategies. MiRNA-based gene therapy targeting dereg-
ulated miRNAs will be the future tool for cancer
treatment. Using data from miRNA profiling and knowl-
edge of familial history of a certain diseases will help in
developing miRNA-based personalized therapy. Detailed
understanding of the characteristic miRNA abnormalities
could contribute to novel approaches in early diagnosis
and treatment of different diseases including cancer and
can serve as a biomarker for cancer. miRNA expression
profiling eventually assist physicians in providing patients
with accurate diagnosis, personalized therapy, and treat-
ment outcome.
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